Oxford, UK – 02 June 2014. OGT, The Molecular Genetics Company, has announced that following its acquisition of CytoCell® in March, it will directly sell CytoCell products to the North American market from the 1st June 2014. New and existing CytoCell customers in North America will now benefit from OGT’s expert and experienced sales and support infrastructure, which will be further enhanced through additional appointments in the coming months.
OGT’s acquisition of CytoCell saw the addition of a portfolio of Fluorescence In Situ Hybridisation (FISH) probes to its CytoSure® cytogenetics array and Genefficiency™ next generation sequencing products and services, expanding the company’s genomic medicine offering.
Dr Martin Lawrie, Managing Director of CytoCell said: “The global cytogenetics market is predicted to grow by 23% a year to $2 billion by 2019, and with North America accounting for approximately 50% of the market, OGT is now well placed to better serve this increasing customer base with a wider range of products. The integration of CytoCell into the OGT group has proceeded extremely smoothly with very positive, immediate benefits for our customers. OGT’s excellent and expanding sales team will provide our customers with the best possible sales and support experience moving forward.”
OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.
For more information on the Company, please visit our website at ogt.com
CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.
About Sysmex Corporation
Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.
For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.
Addition of direct-sales territories follows successes across Europe and APAC and provides customers with enhanced local sales and support services.Read
Clearance enables accurate and easy-to-interpret AML and MDS detection with reduced validation burden.Read
Robust panel enables accurate and comprehensive constitutional genetic aberration screening in one assay.Read